Quarterly ResultAug 11, 2026, 04:15 PM
Taysha Gene Therapies Q2 Net Loss $(46.6)M; Raises $215.6M
AI Summary
Taysha Gene Therapies reported a net loss of $(46.6) million for the second quarter of 2026, an increase from $(26.9) million in the prior year, with no revenue generated. For the six months ended June 30, 2026, the net loss was $(89.0) million. The company successfully completed an underwritten public offering in June 2026, raising $215.6 million in net proceeds, significantly boosting its cash and cash equivalents to $455.4 million. Additionally, Taysha recognized a $3.4 million net gain from the termination of its Durham Lease and now holds unencumbered rights to its TSHA-102 program after the Rett Option expired without being exercised.
Key Highlights
- Net loss for Q2 2026 was $(46.6) million, compared to $(26.9) million for Q2 2025.
- Net loss for the six months ended June 30, 2026, was $(89.0) million, compared to $(48.4) million for the same period in 2025.
- Revenue for Q2 2026 was $0, down from $2.0 million in Q2 2025.
- Research and development expenses increased to $38.6 million in Q2 2026 from $20.1 million in Q2 2025.
- General and administrative expenses rose to $12.1 million in Q2 2026 from $8.6 million in Q2 2025.
- Cash and cash equivalents increased to $455.4 million as of June 30, 2026, from $319.8 million as of December 31, 2025.
- Net proceeds from the June 2026 public offering totaled $215.6 million.
- The company recorded a net gain of $3.4 million on lease termination in Q2 2026.
Price Impact
More from TSHA